Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration

Valverde-Megías, A.; Ruiz-Calvo, Aurora; Murciano-Cespedosa, Antonio; Hernández-Ruiz, S; Martínez-de-la-Casa, J.M.; García‐Feijoó, Julián

doi:10.1007/s00417-019-04325-y

Cited by 16 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OCT-segmentation studies enable to report thickness changes in inner retinal layers associated with the treatment of neovascular AMD with ranibizumab (14,15,16,17). Moreover, in an OCT segmentation study that investigated the impact of aging on the outer retinal layer and choroid, it was shown that the RPE and photoreceptor layers and the choroidal thickness decreased with increasing age (26).…”

Section: Discussionmentioning

confidence: 99%

“…In a study evaluating the effect of intravitreal ranibizumab treatment of neovascular AMD on all retinal layers, it was reported that there was a significant thinning in the inner retina layers after one year of treatment, and a significant decrease in total outer retinal layer and RPE thickness was restricted to occur for the first three months (14). However, the lack of a control group in the relevant study cannot exclude the effect of the natural course of the disease in this thinning.…”

Section: Discussionmentioning

confidence: 99%

“…Non-etheless, VEGF is a mediator with vital importance for retinal photoreceptors, Müller cells, and RPE as well as for the integrity of choriocapillaris (12,13). Inner retinal layers with a peripapillary nerve and retinal ganglion cell layer rather than outer retinal layer have become more extensively addressed by the segmentation studies in AMD patients with limited data on SD-OCT-based automatic segmentation analysis of outer retinal layer in relation to visual function in neovascular AMD patients (8,14,15,16,17). Hence, whether the VEGF suppression has potential age independent hazards on the outer retina remains an enigma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Impact of Intravitreal Ranibizumab Treatment on Outer Retinal Layer Thickness in Neovascular Age-related Macular Degeneration

Gediz¹,

Kaim²

2020

hamidiyemedj

View full text Add to dashboard Cite

Amaç: İntravitreal ranibizumab enjeksiyonu ile tedavi edilen yaşa bağlı maküla dejenerasyonu (YBMD) hastalarında dış retinal tabaka kalınlığının (DRTK) spektral-domain optik koherens tomografi (SD-OKT) ile değerlendirilmesi. Gereç ve Yöntemler: Tek taraflı neovasküler YBMD nedeniyle intravitreal ranibizumab tedavisi almış en az 24 aylık takibi olan hastalar retrospektif olarak incelendi. Kuru tip YBMD olan diğer gözler kontrol grubu olarak kabul edildi. Başvuru anındaki, 12. aydaki ve 24. aydaki en iyi düzeltilmiş görme keskinlikleri (EİDGK) ve SD-OKT'deki DRTK değerleri kaydedildi.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Intravitreal Ranibizumab Treatment on Outer Retinal Layer Thickness in Neovascular Age-related Macular Degeneration

Gediz¹,

Kaim²

2020

hamidiyemedj

View full text Add to dashboard Cite

show abstract

“…Compared to patients without preexisting glaucoma, those with concurrent glaucoma or OHT have higher rates of sustained pressure elevation after multiple injections [8][9][10] . The evidence on treatment-associated retinal nerve fiber layer (RNFL) thinning in non-glaucomatous eyes is controversial [11][12][13][14][15] , but studies of glaucomatous eyes suggest that repetitive injections may be associated with accelerated structural change [16][17][18] . These findings call into question the safety of long-term therapy for glaucoma patients, as they may be predisposed to OHT and associated complications.…”

Section: Introductionmentioning

confidence: 99%

Prophylaxis with intraocular pressure lowering medication and glaucomatous progression in patients receiving intravitreal anti-VEGF therapy

Du¹,

Cai²,

Prum³

et al. 2022

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To investigate whether pretreatment with pressure-lowering medication prior to anti-vascular endothelial factor (VEGF) injections had an effect on glaucomatous progression in patients with preexisting glaucoma or ocular hypertension (OHT). METHODS: A total of 66 eyes from 54 patients with a preexisting diagnosis of glaucoma or OHT, treated with six or more anti-VEGF injections were selected for chart review. Primary outcome measures were rate of visual field loss in dB/year, rate of change in retinal nerve fiber layer (RNFL) thickness in microns/year, and need for additional glaucoma intervention. RESULTS: The number of eyes requiring additional glaucoma medication was 5 of 20 (25.0%) and 14 of 46 (30.4%) for the pretreated and non-pretreated groups, respectively. The number of eyes requiring glaucoma laser or surgery was 4 of 20 (20.0%) and 13 of 46 (28.3%) for the pretreated and non-pretreated groups, respectively. Estimated mean rate of pattern standard deviation decline was not significant in either group (P>0.073), with no difference between groups (P=0.332). Although both groups showed significant RNFL change from baseline (P<0.011), no difference was detected between groups (P=0.467). CONCLUSION: Pretreatment has no detectable effect on structural or functional glaucomatous progression. Patients receiving repeated injections may be at risk for glaucomatous complications requiring invasive intervention.

show abstract

“…Hence, it is important to know whether and to which extent macular diseases lead to peripapillary RNFL loss potentially interfering with the RNFL analysis. Despite the high prevalence of both AMD and glaucoma, only few studies have addressed this question [4][5][6], some of them with regard to the question as to whether anti-VEGF therapy interferes with the peripapillary RNFL [7].…”

Section: Introductionmentioning

confidence: 99%

Thinner temporal peripapillary retinal nerve fibre layer in Stargardt disease detected by optical coherence tomography

Reich

Lübke

Joachimsen

et al. 2020

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate peripapillary retinal nerve fibre layer (RNFL) thickness measured by spectral domain optical coherence tomography (OCT) in patients with Stargardt disease (STGD). Methods A cross-sectional, monocentric, observational case-control study. Twenty patients (39 eyes) with ABCA4 mutations graded according to the Fishman STGD classification were included. RNFL measurement was performed using Heidelberg Spectralis SD-OCT. RNFL thickness in STGD patients was compared to age-matched data of healthy individuals provided by the device’s manufacturer. A manual readjustment of the optic disc-fovea angle was performed when needed. Results The mean age at first diagnosis of STGD was 22.9 years (range 9 to 50) and 39.1 years (range 18 to 74) at the time of examination. Thirty-nine percent of eyes (15 eyes) needed manual adjustment of the optic disc-fovea angle due to malfixation of the patients during OCT. The temporal quadrant corresponding to the macula showed a RNFL 16% thinner than controls (mean − 12 μm, 95%CI − 9 to −15 μm). However, global RNFL thickness did not differ from controls due to increased RNFL thickness of 12% in the nasal sectors. Duration and stage of STGD were not correlated to thinner RNFL. Conclusion STGD seems to be associated with thinner peripapillary RNFL in the sector of axons projecting to the degenerated macular area. It is yet unclear as to whether this results from anterograde transneuronal degeneration of direct injury to retinal ganglion cells.

show abstract

Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration

Cited by 16 publications

References 21 publications

The Impact of Intravitreal Ranibizumab Treatment on Outer Retinal Layer Thickness in Neovascular Age-related Macular Degeneration

The Impact of Intravitreal Ranibizumab Treatment on Outer Retinal Layer Thickness in Neovascular Age-related Macular Degeneration

Prophylaxis with intraocular pressure lowering medication and glaucomatous progression in patients receiving intravitreal anti-VEGF therapy

Thinner temporal peripapillary retinal nerve fibre layer in Stargardt disease detected by optical coherence tomography

Contact Info

Product

Resources

About